$91.06
0.460.51%
At Close: -
$91.06
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Haemonetics (NYSE:HAE) Stock, Analyst Ratings, Price Targets, Forecasts
Haemonetics Corp has a consensus price target of $101.13 based on the ratings of 8 analysts. The high is $125 issued by JMP Securities on May 10, 2024. The low is $60 issued by Morgan Stanley on January 7, 2022. The 3 most-recent analyst ratings were released by Needham, JMP Securities, and Barrington Research on June 12, 2024, May 10, 2024, and May 10, 2024, respectively. With an average price target of $114.67 between Needham, JMP Securities, and Barrington Research, there's an implied 25.92% upside for Haemonetics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
JMP Securities
Barrington Research
Citigroup
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Haemonetics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/12/2024 | Buy Now | 23% | Needham | Mike Matson | → $112 | Upgrade | Hold → Buy | Get Alert |
| 05/10/2024 | Buy Now | 37.27% | JMP Securities | David Turkaly | $115 → $125 | Maintains | Market Outperform | Get Alert |
| 05/10/2024 | Buy Now | 17.5% | Barrington Research | Michael Petusky | $105 → $107 | Maintains | Outperform | Get Alert |
| 05/10/2024 | Buy Now | — | Needham | Mike Matson | — | Reiterates | → Hold | Get Alert |
| 04/12/2024 | Buy Now | 15.31% | Barrington Research | Michael Petusky | $105 → $105 | Maintains | Outperform | Get Alert |
| 02/13/2024 | Buy Now | 15.31% | Barrington Research | Michael Petusky | → $105 | Reiterates | Outperform → Outperform | Get Alert |
| 11/03/2023 | Buy Now | 15.31% | Barrington Research | Michael Petusky | $114 → $105 | Maintains | Outperform | Get Alert |
| 10/02/2023 | Buy Now | 3.23% | Citigroup | Joanne Wuensch | $90 → $94 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | 25.19% | Barrington Research | Michael Petusky | $111 → $114 | Maintains | Outperform | Get Alert |
| 05/12/2023 | Buy Now | 21.9% | Barrington Research | Michael Petusky | $103 → $111 | Maintains | Outperform | Get Alert |
| 05/12/2023 | Buy Now | 5.42% | Morgan Stanley | Drew Ranieri | $88 → $96 | Maintains | Equal-Weight | Get Alert |
| 05/12/2023 | Buy Now | 26.29% | JMP Securities | David Turkaly | $105 → $115 | Maintains | Market Outperform | Get Alert |
| 02/08/2023 | Buy Now | -3.36% | Morgan Stanley | Drew Ranieri | $84 → $88 | Maintains | Equal-Weight | Get Alert |
| 02/08/2023 | Buy Now | 4.33% | Citigroup | Joanne Wuensch | $92 → $95 | Maintains | Neutral | Get Alert |
| 02/08/2023 | Buy Now | 13.11% | Barrington Research | Michael Petusky | $94 → $103 | Maintains | Outperform | Get Alert |
| 02/08/2023 | Buy Now | 26.29% | Mizuho | Anthony Petrone | $110 → $115 | Maintains | Buy | Get Alert |
| 01/24/2023 | Buy Now | 20.8% | Mizuho | Anthony Petrone | $100 → $110 | Maintains | Buy | Get Alert |
| 01/06/2023 | Buy Now | -7.75% | Morgan Stanley | Drew Ranieri | $90 → $84 | Maintains | Equal-Weight | Get Alert |
| 12/12/2022 | Buy Now | 1.03% | Citigroup | Joanne Wuensch | $88 → $92 | Maintains | Neutral | Get Alert |
| 11/08/2022 | Buy Now | 3.23% | Barrington Research | Michael Petusky | $88 → $94 | Maintains | Outperform | Get Alert |
| 11/08/2022 | Buy Now | -1.16% | Morgan Stanley | Drew Ranieri | $85 → $90 | Maintains | Equal-Weight | Get Alert |
| 11/08/2022 | Buy Now | 9.82% | Mizuho | Anthony Petrone | $90 → $100 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | 15.31% | JMP Securities | David Turkaly | $90 → $105 | Maintains | Market Outperform | Get Alert |
| 11/08/2022 | Buy Now | 9.82% | Raymond James | Andrew Cooper | $88 → $100 | Maintains | Outperform | Get Alert |
| 11/08/2022 | Buy Now | -3.36% | Citigroup | Joanne Wuensch | $80 → $88 | Maintains | Neutral | Get Alert |
| 10/13/2022 | Buy Now | -1.16% | Mizuho | Anthony Petrone | → $90 | Initiates | → Buy | Get Alert |
| 10/11/2022 | Buy Now | -6.65% | Morgan Stanley | Drew Ranieri | $74 → $85 | Maintains | Equal-Weight | Get Alert |
| 08/11/2022 | Buy Now | -1.16% | JMP Securities | David Turkaly | $80 → $90 | Maintains | Market Outperform | Get Alert |
| 08/11/2022 | Buy Now | -18.73% | Morgan Stanley | Drew Ranieri | $70 → $74 | Maintains | Equal-Weight | Get Alert |
| 08/11/2022 | Buy Now | -3.36% | Barrington Research | Michael Petusky | $77 → $88 | Maintains | Outperform | Get Alert |
| 08/11/2022 | Buy Now | -3.36% | Raymond James | Andrew Cooper | $76 → $88 | Maintains | Outperform | Get Alert |
| 07/01/2022 | Buy Now | -23.13% | Morgan Stanley | Drew Ranieri | $60 → $70 | Maintains | Equal-Weight | Get Alert |
| 07/01/2022 | Buy Now | -16.54% | Raymond James | Andrew Cooper | $63 → $76 | Maintains | Outperform | Get Alert |
| 05/11/2022 | Buy Now | -34.11% | Morgan Stanley | Drew Ranieri | $64 → $60 | Maintains | Equal-Weight | Get Alert |
| 05/11/2022 | Buy Now | -30.81% | Raymond James | Andrew Cooper | $66 → $63 | Maintains | Outperform | Get Alert |
| 02/09/2022 | Buy Now | -27.52% | Raymond James | Andrew Cooper | $70 → $66 | Maintains | Outperform | Get Alert |
| 01/27/2022 | Buy Now | — | Needham | Mike Matson | — | Downgrade | Buy → Hold | Get Alert |
| 01/07/2022 | Buy Now | -34.11% | Morgan Stanley | David Lewis | $68 → $60 | Maintains | Equal-Weight | Get Alert |
| 12/15/2021 | Buy Now | — | Citigroup | Joanne Wuensch | — | Downgrade | Buy → Neutral | Get Alert |
| 11/10/2021 | Buy Now | -12.15% | JMP Securities | David Turkaly | — | Maintains | Market Outperform | Get Alert |
| 11/10/2021 | Buy Now | -23.13% | Raymond James | Andrew Cooper | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Haemonetics (HAE) stock?
The latest price target for Haemonetics (NYSE:HAE) was reported by Needham on June 12, 2024. The analyst firm set a price target for $112.00 expecting HAE to rise to within 12 months (a possible 23.00% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Haemonetics (HAE)?
The latest analyst rating for Haemonetics (NYSE:HAE) was provided by Needham, and Haemonetics upgraded their buy rating.
When was the last upgrade for Haemonetics (HAE)?
The last upgrade for Haemonetics Corp happened on June 12, 2024 when Needham raised their price target to $112. Needham previously had a hold for Haemonetics Corp.
When was the last downgrade for Haemonetics (HAE)?
The last downgrade for Haemonetics Corp happened on January 27, 2022 when Needham changed their price target from N/A to N/A for Haemonetics Corp.
When is the next analyst rating going to be posted or updated for Haemonetics (HAE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Haemonetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Haemonetics was filed on June 12, 2024 so you should expect the next rating to be made available sometime around June 12, 2025.
Is the Analyst Rating Haemonetics (HAE) correct?
While ratings are subjective and will change, the latest Haemonetics (HAE) rating was a upgraded with a price target of $0.00 to $112.00. The current price Haemonetics (HAE) is trading at is $91.06, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.